Natco Pharma share price has plunged 5% and is presently trading at Rs 888.7.
Meanwhile, the BSE HEALTHCARE index is at 46,290.3 .
Among the top losers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (down 1.8%) and METROPOLIS HEALTHCARE (down 1.6%).
ERIS LIFESCIENCES (up 2.1%) and Aurobindo Pharma (up 1.4%) are among the top gainers today.
Over the last one year, Natco Pharma has moved up from Rs 878.4 to Rs 888.7, registering a gain of Rs 10.3 (up 1.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 42,648.8 to 46,290.3, registering a gain of 8.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were LAURUS LABS (up 126.1%), GRANULES INDIA (up 48.9%) and Glenmark Pharma (up 45.9%).
Independence Day Offer: Get Our 4 Research Services at the Price of 1
The BSE Sensex is at 73,758.8 (down 1.2%).
The top losers among the BSE Sensex today are TCS (down 7.2%) and Tech Mahindra (down 5.0%). The most traded stocks in the BSE Sensex are TCS and ITC.
In the meantime, NSE Nifty is at 23,265.3 (down 0.9%). TCS and Tech Mahindra are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved down from 81,373.8 to 73,758.8, registering a loss of 7,614.9 points (down 9.4%).
Natco Pharma net profit fell 42.5% YoY to Rs 2,333 million for the quarter ended March 2026, compared to a profit of Rs 4,060 million a year ago. Net sales declined 39.5% to Rs 7,391 million during the period as against Rs 12,210 million in January-March 2025.
For the year ended March 2025, Natco Pharma reported 35.7% increase in net profit to Rs 18,834 million compared to net profit of Rs 13,883 million during FY24. Revenue of the company grew 10.8% to Rs 44,295 million during FY25.
The current Price to earnings ratio of Natco Pharma, based on rolling 12 month earnings, stands at 11.6.
Image source: DNY59/www.istockphoto.com
Equitymaster requests your view! Post a comment on "Natco Pharma Plunges 5%; BSE HEALTHCARE Index Up 0.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!